Pre-clinical data showed activity of ALK inhibitors (i.e., crizotinib and TAE684) in ROS-1-rearranged NSCLC cell lines given the high degree of homology between ALK and ROS-1 tyrosine kinase domains (25). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.